NCT07788833
Evaluation of RSB11-HI Postbiotic Supplementation for Supporting Weight Management, Metabolic Wellness, and Quality of Life in Healthy Adults
StatusActive, Not Recruiting
PhaseNot applicable
SponsorAble Biolabs, LLC
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 15 words Show 5 more changesShow less
- Enrollment closed, study ongoing
- Start date changed from estimate of Aug 2026 to Aug 5, 2026
- Secondary endpoints: details revised at 6 of 7 entries
- Study description revised
- Site details revised
- Notable Eligibility criteria shortened, about 14 words
- Secondary endpoints: details revised at 5 of 7 entries
- Study title shortened, about 11 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in Body Weight From Baseline to Week 8
Timeframe: Baseline to Week 8
Secondary (7)
Change in Body Mass Index (BMI)
Change in Waist Circumference
Change in Appetite and Satiety
Change in General Well-Being
Change in Perceived Stress
Show 2 moreShow less
Change in Gastrointestinal Symptoms
Change in Menopause-Related Quality of Life
Arms and interventions
RSB11-HI Heat-Inactivated PostbioticExperimental
Participants assigned to this arm will receive RSB11-HI Heat-Inactivated Postbiotic orally once daily for 8 consecutive weeks according to the study dosing instructions.
PlaceboPlacebo comparator
Participants assigned to this arm will receive the matched placebo orally once daily for 8 consecutive weeks according to the study dosing instructions. The placebo is identical in appearance, packaging, labeling, and administration schedule to the RSB11-HI study product to maintain blinding.
Dietary supplements: RSB11-HI Heat-Inactivated Postbiotic
Other: Placebo
Sites
1 site in 1 country
- Able Biolabs LLCDallas, Texas, United States